# Futibatinib in Combination With (Chemo)Immunotherapy in Colorectal Cancer and Other Solid Tumor Entities

Source: https://onco.cc/trials/nct06722183/  
OnCo record `nct06722183` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of tislelizumab in colorectal cancer, run by Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, now recruiting.

## Summary

Futibatinib in Combination With (Chemo)Immunotherapy in Colorectal Cancer and Other Solid Tumor Entities is a phase 2, interventional study registered as NCT06722183 by Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, with a registry enrolment figure of 33 participants, started 2025-12-16 and due to reach its primary completion in 2028-03. Interventions recorded: Futibatinib orally administered; Tislelizumab (i.v. 200mg). Conditions listed: Colorectal Cancer. Primary outcome: Overall Response Rate (ORR) according to RECIST v1.1. Colorectal eligibility wording from the registry: "• Specific for FUTURE-001: Histological or cytological confirmation of colorectal adenocarcinoma that is unresectable and/or metastatic with known RAS-, BRAF and MSI- status". Sites: Germany. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-24
- Also known as: FUTURE
- Tags: ctgov-ingest; colorectal-deep-dive
- Registry id: NCT06722183
- Phase: 2
- Setting: FUTURE Platform Trial - A Phase II Platform Trial of Futibatinib in Combination With (Chemo)Immunotherapy in Colorectal Cancer and Other Solid Tumor Entities
- Sponsor: Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
- Enrolled: 33

## Sources

- ClinicalTrials.gov NCT06722183: https://clinicaltrials.gov/study/NCT06722183

## Connected records

- cancers: [Colon cancer (adenocarcinoma of the colon)](https://onco.cc/cancers/colon-cancer/), [Mismatch-repair deficient (MSI-high) colorectal cancer](https://onco.cc/cancers/msi-high-colorectal/), [Rectal cancer](https://onco.cc/cancers/rectal-cancer/)
- technologies: [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/)
- drugs: [Tislelizumab](https://onco.cc/drugs/tislelizumab/)
- terms: [Colorectal cancer trials open today (registry snapshot)](https://onco.cc/terms/colorectal-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct06722183.json